Becton Dickinson and Co (BDX) Holdings Lessened by Cambridge Trust Co.

Cambridge Trust Co. reduced its holdings in Becton Dickinson and Co (NYSE:BDX) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 122,379 shares of the medical instruments supplier’s stock after selling 365 shares during the quarter. Becton Dickinson and accounts for about 1.9% of Cambridge Trust Co.’s investment portfolio, making the stock its 14th largest holding. Cambridge Trust Co.’s holdings in Becton Dickinson and were worth $27,575,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in BDX. FMR LLC lifted its stake in shares of Becton Dickinson and by 7.6% in the second quarter. FMR LLC now owns 16,067,452 shares of the medical instruments supplier’s stock worth $3,849,118,000 after buying an additional 1,129,688 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Becton Dickinson and in the third quarter worth about $251,000. Atria Investments LLC lifted its stake in shares of Becton Dickinson and by 38.9% in the third quarter. Atria Investments LLC now owns 1,488 shares of the medical instruments supplier’s stock worth $388,000 after buying an additional 417 shares in the last quarter. First Hawaiian Bank purchased a new position in shares of Becton Dickinson and in the third quarter worth about $2,004,000. Finally, Andra AP fonden lifted its stake in shares of Becton Dickinson and by 73.3% in the third quarter. Andra AP fonden now owns 10,400 shares of the medical instruments supplier’s stock worth $2,714,000 after buying an additional 4,400 shares in the last quarter. Institutional investors own 86.28% of the company’s stock.

In other Becton Dickinson and news, EVP Ribo Alberto Mas sold 4,530 shares of Becton Dickinson and stock in a transaction dated Wednesday, November 14th. The shares were sold at an average price of $237.01, for a total transaction of $1,073,655.30. Following the completion of the sale, the executive vice president now directly owns 14,596 shares in the company, valued at $3,459,397.96. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP James W. Borzi sold 5,887 shares of Becton Dickinson and stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $252.37, for a total transaction of $1,485,702.19. Following the sale, the executive vice president now owns 6,013 shares of the company’s stock, valued at $1,517,500.81. The disclosure for this sale can be found here. Insiders have sold 34,606 shares of company stock worth $8,356,772 over the last ninety days. 0.12% of the stock is owned by insiders.



Several equities analysts have recently weighed in on BDX shares. TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 price target on the stock in a research note on Tuesday, January 8th. Citigroup decreased their price target on shares of Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a research note on Tuesday, November 13th. Deutsche Bank started coverage on shares of Becton Dickinson and in a research note on Thursday, December 6th. They issued a “buy” rating and a $280.00 price target on the stock. Finally, Barclays started coverage on shares of Becton Dickinson and in a research note on Monday, October 15th. They issued an “equal weight” rating and a $278.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $253.17.

Shares of BDX stock opened at $242.21 on Monday. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $265.87. The stock has a market cap of $65.17 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.70 and a beta of 1.23.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The company had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the firm earned $2.48 earnings per share. Becton Dickinson and’s quarterly revenue was up 35.1% compared to the same quarter last year. On average, research analysts anticipate that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 8th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date of this dividend is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

WARNING: “Becton Dickinson and Co (BDX) Holdings Lessened by Cambridge Trust Co.” was published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://dakotafinancialnews.com/2019/02/11/becton-dickinson-and-co-bdx-holdings-lessened-by-cambridge-trust-co.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: SEC Filing

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply